Drug Combo Delivers High Response Rate in Pancreatic Cancer Patients
A clinical trial combining vopimetostat and daraxonrasib shows durable responses in most pancreatic cancer patients treated.
Summary
Pancreatic cancer is one of the hardest cancers to treat, with very low survival rates. New early-stage trial data reveals that combining two experimental drugs — vopimetostat from Tango Therapeutics and daraxonrasib from Revolution Medicines — produced durable responses in the large majority of patients. Daraxonrasib had already drawn attention for delivering unprecedented results on its own. The combination trial suggests a synergistic effect may further improve outcomes. This is early-stage data, meaning larger confirmatory trials are needed, but the results represent a potentially meaningful step forward in treating a cancer type that has seen little progress for decades.
Detailed Summary
Pancreatic cancer remains one of oncology's most formidable challenges, with a five-year survival rate under 15% and limited treatment advances in recent decades. Any signal of durable response in this disease is considered clinically significant, making this new combination trial data noteworthy.
Revolution Medicines' daraxonrasib had already attracted widespread attention for producing what researchers described as unprecedented outcomes as a standalone therapy in pancreatic cancer. The new data, presented by Tango Therapeutics, shows that combining daraxonrasib with vopimetostat — Tango's experimental epigenetic-targeting agent — yielded durable responses in the large majority of patients enrolled in an early-stage clinical trial.
Vopimetostat is designed to inhibit SETDB1, an epigenetic regulator believed to help cancer cells evade immune detection. Daraxonrasib targets KRAS, a mutation found in roughly 90% of pancreatic cancers and long considered undruggable. The rationale for combining them is to simultaneously block tumor survival signaling and restore immune visibility, potentially creating a more complete anti-tumor response.
For health-conscious individuals and patients tracking cancer therapeutics, this combination approach represents a potential paradigm shift. KRAS-targeted therapies have opened a new chapter in oncology, and pairing them with epigenetic modulators could become a broader strategy across multiple cancer types beyond pancreatic disease.
Important caveats apply. This is an early-stage trial with a limited patient population, and 'large majority' response rates need to be quantified and validated in larger, randomized studies. The article is gated behind a paywall, limiting access to full data, patient numbers, response duration, and safety profiles. Regulatory approval remains distant. Still, for a disease with so few effective options, these early signals warrant close attention from patients, clinicians, and researchers alike.
Key Findings
- Combining vopimetostat and daraxonrasib produced durable responses in most pancreatic cancer patients in early-stage trial.
- Daraxonrasib targets KRAS mutations, present in ~90% of pancreatic cancers and historically considered undruggable.
- Vopimetostat targets epigenetic pathways that may help cancer cells escape immune detection.
- Results build on daraxonrasib's prior standalone data showing unprecedented outcomes in pancreatic cancer.
- Early-phase data only; larger randomized trials needed to confirm efficacy and safety.
Methodology
This is a news report from STAT News, a credible specialized biomedical journalism outlet. The article summarizes early-stage clinical trial data presented by Tango Therapeutics. Full methodology is paywalled, limiting independent verification of patient numbers, response definitions, and follow-up duration.
Study Limitations
The full article is behind a STAT+ paywall, preventing review of complete trial data, patient cohort size, response rate percentages, and adverse event profiles. Early-stage trial results frequently do not replicate in larger phase trials. No regulatory approval or timeline has been established for either drug in this indication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.